Flow cytometric analysis of AM22.1 antibody-mediated neutralization of Mouse (Left Panel) or Human (Right Panel) IL-22-induced phosphorylation of Stat3 Y705 by human HT-29 cells. Left Panel: Serum-starved cells from the human HT-29 (Colorectal Carcinoma, ATCC HTB-38) cell line were either not stimulated (Unstim) or were stimulated for 15 min at 37°C with 25 ng/ml of Recombinant Mouse IL-22 protein (mIL-22) (R&D Systems; Cat. No. 582-ML-010), as indicated. Alternatively, the HT-29 cells were treated with the Recombinant Mouse IL-22 protein either preincubated with 5 µg/ml of Purified NA/LE Mouse Anti-IL-22 antibody (AM22.1) (Cat. No. 568088) or with Purified NA/LE Mouse IgG2a, κ Isotype Control (Iso Ctrl) (Cat. No. 554645) as shown. Right Panel: Similarly, HT-29 cells were either not stimulated (Unstim) or were stimulated for 15 min at 37°C with 25 ng/ml of Recombinant Human IL-22 protein (hIL-22) (R&D Systems; Cat. No. 782-ML-010), as indicated. Alternatively, the HT-29 cells were treated with either the Recombinant Human IL-22 protein preincubated with 5 µg/ml of Purified NA/LE Mouse Anti-IL-22 antibody (AM22.1) (Cat. No. 568088) or with Purified NA/LE Mouse IgG2a, κ Isotype Control (Iso Ctrl) (Cat. No. 554645) as shown. The HT-29 cells were fixed with BD Cytofix™ Fixation Buffer (Cat. No. 554655), permeabilized with BD Phosflow™ Perm Buffer III (Cat. No. 558050), and then stained with BD Phosflow™ PE Mouse Anti-Stat3 (pY705) antibody (Cat. No. 612569). The fluorescence histograms showing Stat3 (pY705) expression were derived from gated events with the forward and side light-scatter characteristics of intact cells. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System equipped with a Yellow-Green Laser and FlowJo™ software. Data shown on this TDS/eCatalog Product Page are not lot specific.
Flow cytometric analysis of AM22.1 antibody-mediated neutralization of Mouse (Left Panel) or Human (Right Panel) IL-22-induced phosphorylation of Stat3 Y705 by human HT-29 cells. Left Panel: Serum-starved cells from the human HT-29 (Colorectal Carcinoma, ATCC HTB-38) cell line were either not stimulated (Unstim) or were stimulated for 15 min at 37°C with 25 ng/ml of Recombinant Mouse IL-22 protein (mIL-22) (R&D Systems; Cat. No. 582-ML-010), as indicated. Alternatively, the HT-29 cells were treated with the Recombinant Mouse IL-22 protein either preincubated with 5 µg/ml of Purified NA/LE Mouse Anti-IL-22 antibody (AM22.1) (Cat. No. 568088) or with Purified NA/LE Mouse IgG2a, κ Isotype Control (Iso Ctrl) (Cat. No. 554645) as shown. Right Panel: Similarly, HT-29 cells were either not stimulated (Unstim) or were stimulated for 15 min at 37°C with 25 ng/ml of Recombinant Human IL-22 protein (hIL-22) (R&D Systems; Cat. No. 782-ML-010), as indicated. Alternatively, the HT-29 cells were treated with either the Recombinant Human IL-22 protein preincubated with 5 µg/ml of Purified NA/LE Mouse Anti-IL-22 antibody (AM22.1) (Cat. No. 568088) or with Purified NA/LE Mouse IgG2a, κ Isotype Control (Iso Ctrl) (Cat. No. 554645) as shown. The HT-29 cells were fixed with BD Cytofix™ Fixation Buffer (Cat. No. 554655), permeabilized with BD Phosflow™ Perm Buffer III (Cat. No. 558050), and then stained with BD Phosflow™ PE Mouse Anti-Stat3 (pY705) antibody (Cat. No. 612569). The fluorescence histograms showing Stat3 (pY705) expression were derived from gated events with the forward and side light-scatter characteristics of intact cells. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System equipped with a Yellow-Green Laser and FlowJo™ software. Data shown on this TDS/eCatalog Product Page are not lot specific.
Product Details
BD Pharmingen™
IL-22; IL22; interleukin 22; Interleukin-22
Human (QC Testing), Mouse (Tested in Development)
Mouse C57BL/6 IgG2a, κ
Mouse IL-22 Recombinant Protein
Blocking, Intracellular staining (flow cytometry) (Tested During Development)
1.0 mg/ml
No azide/low endotoxin: Aqueous buffered solution containing no preservative, sterile filtered(0.2µm pore size membrane). Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
RUO
Preparation And Storage
Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- An isotype control should be used at the same concentration as the antibody of interest.
Companion Products
Stain Buffer (FBS) RUO
Size
500 mL
Cat No.
554656
Stain Buffer (BSA) RUO
Size
500 mL
Cat No.
554657
Purified NA/LE Mouse IgG2a, κ Isotype Control RUO
Size
0.5 mg
Cat No.
554645
Fixation Buffer RUO
Size
100 mL
Cat No.
554655
Perm Buffer III RUO
Size
125 mL
Cat No.
558050
PE Mouse Anti-Stat3 (pY705) RUO
Size
50 Tests
Cat No.
612569
568088 Rev. 1
Antibody Details
AM22.1
The AM22.1 monoclonal antibody specifically recognizes mouse Interleukin-22 (IL-22) and crossreacts with human IL-22. IL-22 is a member of the IL-10 cytokine family. IL-22 is expressed by some activated T cell subsets including Th17-, Th22- and Th1-like T cells, lymphoid tissue inducer (LTi) cells, as well as some natural killer (NK) cells and innate lymphoid cell (ILC) subsets. IL-22 binds to a heteromeric cell surface IL-22 receptor complex that is comprised of IL-22R1 and IL-10Rβ chains. When IL-22 ligand-bound, this receptor transduces JAK-STAT signaling (eg, phosphorylation of Stat3 at Y705) intracellularly. IL-22 acts on epithelial cells of the skin and mucosal tissues and plays a major role in mediating innate antimicrobial responses by inducing the expression of various mediators including antimicrobial proteins and chemokines. It also plays a roles in wound healing and maintaining epithelial integrity. IL-22 can also act on hepatocytes to stimulate increased acute-phase protein production. Aberrant overexpression of IL-22 can result in certain inflammatory disorders including psoriasis.
568088 Rev. 1
Format Details
NA/LE
NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
NA/LE
568088 Rev.1
Citations & References
Development References (6)
-
Disson O, Blériot C, Jacob JM, et al. Peyer's patch myeloid cells infection by Listeria signals through gp38(+) stromal cells and locks intestinal villus invasion. J Exp Med. 2018; 215(11):2936-2954. (Clone-specific: In vivo exacerbation, Neutralization). View Reference
-
Pineda MA, Rodgers DT, Al-Riyami L, Harnett W, Harnett MM. ES-62 protects against collagen-induced arthritis by resetting interleukin-22 toward resolution of inflammation in the joints. Arthritis Rheumatol. 2014; 66(6):1492-503. (Clone-specific). View Reference
-
Reynders, A., N. Yessaad, et al. Identity, regulation and in vivo function of gut NKp46+RORgammat+ and NKp46+RORgammat- lymphoid cells. EMBO J. 2011; 30:2934-2947. (Biology). View Reference
-
Ronchi, F., C. Basso, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1beta production by myeloid cells. Nature Commun. 2016; 7:11541. (Biology).
-
Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system.. Nat Rev Drug Discov. 2014; 13(1):21-38. (Biology). View Reference
-
Van Belle AB, de Heusch M, Lemaire MM, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.. J Immunol. 2012; 188(1):462-9. (Clone-specific: Blocking, Functional assay, In vivo exacerbation, Neutralization). View Reference
568088 Rev. 1
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
